Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended June 30, 2016
Natco Pharma Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended June 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Shareholding for the Period Ended June 30, 2016
Natco Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2016. For more details, kindly Click here Natco Pharma gains on USFDA nod for generic Glycopyrrolate tablets
The stock was trading higher by 4% to Rs 552, extending its Wednesday's 6% rally on the BSE Clarifies on News Item
With reference to new flashed on CNBC TV 18 stating "NATCO Pharma gets USFDA nod for Glycopyrrolate", Natco Pharma Ltd has submitted to BSE a copy of Clarification is enclosed. Clarification sought from Natco Pharma Ltd
The Exchange has sought clarification from Natco Pharma Ltd on June 23, 2016, with reference to new flashed on CNBC TV 18 stating "NATCO Pharma gets USFDA nod for Glycopyrrolate".The reply is awaited. Why Sandeep Raina is betting on these midcap stocks
Natco Pharma is going to be a multi-bagger in the next two to four years Natco will out-license molecules to big pharma: Amit Rajan, Director, Celogen Life
Amit Rajan, Director, Celogen Life says that Micro Labs will quickly come out of the FDA and midcap space as they have a good R&D; pipeline. Natco Pharma: Healthy prospects
Niche opportunities in the US and robust growth in India bode well for the company Natco Pharma's partner MylanInc gets USFDA nod for cancer drug
NEW DELHI: Natco Pharma today said its marketing partner Mylan Inc has received tentative approval from the US health regulator for selling generic Sorafenib tablets used for treatment of cancer in the American market. The company's marketing partner Mylan Inc has received a tentative approval from the United States Food and Drug Administration (USFDA) for abbreviated new drug application (ANDA) for Sorafenib tablets in the strength of 200 mg, Natco Pharma said in a filing to BSE. "Natco and Mylan have filed an ANDA containing a Paragraph IV certification for this product," it added. The company manufactures this product at its Kothur facility in Telangana, Natco Pharma said. Bayer Healthcare LLC, Bayer Healthcare Pharmaceuticals Inc and Onyx Pharmaceuticals Inc sell Sorafenib tablets, 200mg under the brand name 'Nexavar' in the U S market, it added. "For the 12 months ending December 31, 2015, Nexavar had U S sales of approximately USD 300 million," Natco said quoting Bayer's Annual Report. Nexavar is indicated for the treatment of certain types of cancers "including unresectable hepatocellular carcinoma and advanced renal cell carcinoma", it added. Natco stock was trading at Rs 509.65, up 6.72 per cent, on BSE. NATCO receives USFDA tentative approval for Sorafenib Tablets, 200mg
Natco Pharma Ltd has informed BSE regarding a Press Release dated June 03, 2016 titled "NATCO receives USFDA tentative approval for Sorafenib Tablets, 200mg".